Table 3 Subgroup analysis of 30-day clinical success according to source of infection
30-day clinical success | Cefoxitin n = 63 (57%) | Carbapenem n = 47 (43%) | OR (95% CI) | p value |
|---|---|---|---|---|
Source of bacteremia | ||||
Central line associated | 20/24 (83%) | 10/12 (83%) | 1.0 (0.1–8.5) | 1.00 |
Pneumonia | 1/7 (14%) | 3/14 (21%) | 0.6 (0.1–10.0) | 1.00 |
Urinary tract | 8/13 (61%) | 2/3 (67%) | 0.8 (0.1–19.7) | 1.00 |
Intra-abdominal | 2/8 (25%) | 1/4 (25%) | 1.0 (0.1–78.4) | 1.00 |
Unknown | 4/8 (50%) | 7/9 (78%) | 0.3 (0.2–3.4) | .335 |